Requirement for safety monitoring for approved multiple sclerosis therapies

An overview

P. S. Rommer, U. K. Zettl, B. Kieseier, H. P. Hartung, T. Menge, Elliot Frohman, Benjamin Greenberg, B. Hemmer, Olaf Stuve

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Summary: During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk-benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appear to be more effective, but potential risks might be more severe. The potential complications of some novel therapies might not even have been identified to their full extent. This review is aimed at the clinical neurologist in that it offers insights into potential adverse events of each of the approved MS therapeutics: interferon beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod and teriflunomide, as well as recently approved therapeutics such as dimethyl fumarate and alemtuzumab. It also provides recommendations for monitoring the different drugs during therapy in order to avoid common side effects.

Original languageEnglish (US)
Pages (from-to)397-407
Number of pages11
JournalClinical and Experimental Immunology
Volume175
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Multiple Sclerosis
Safety
Interferon-beta
Therapeutics
Mitoxantrone
Drug Therapy
Pharmaceutical Preparations
Glatiramer Acetate

Keywords

  • Activation
  • Acute respiratory distress syndrome
  • Multiple sclerosis (MS)

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Requirement for safety monitoring for approved multiple sclerosis therapies : An overview. / Rommer, P. S.; Zettl, U. K.; Kieseier, B.; Hartung, H. P.; Menge, T.; Frohman, Elliot; Greenberg, Benjamin; Hemmer, B.; Stuve, Olaf.

In: Clinical and Experimental Immunology, Vol. 175, No. 3, 03.2014, p. 397-407.

Research output: Contribution to journalArticle

Rommer, P. S. ; Zettl, U. K. ; Kieseier, B. ; Hartung, H. P. ; Menge, T. ; Frohman, Elliot ; Greenberg, Benjamin ; Hemmer, B. ; Stuve, Olaf. / Requirement for safety monitoring for approved multiple sclerosis therapies : An overview. In: Clinical and Experimental Immunology. 2014 ; Vol. 175, No. 3. pp. 397-407.
@article{1b065e4454a44472a84235767c3d797c,
title = "Requirement for safety monitoring for approved multiple sclerosis therapies: An overview",
abstract = "Summary: During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk-benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appear to be more effective, but potential risks might be more severe. The potential complications of some novel therapies might not even have been identified to their full extent. This review is aimed at the clinical neurologist in that it offers insights into potential adverse events of each of the approved MS therapeutics: interferon beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod and teriflunomide, as well as recently approved therapeutics such as dimethyl fumarate and alemtuzumab. It also provides recommendations for monitoring the different drugs during therapy in order to avoid common side effects.",
keywords = "Activation, Acute respiratory distress syndrome, Multiple sclerosis (MS)",
author = "Rommer, {P. S.} and Zettl, {U. K.} and B. Kieseier and Hartung, {H. P.} and T. Menge and Elliot Frohman and Benjamin Greenberg and B. Hemmer and Olaf Stuve",
year = "2014",
month = "3",
doi = "10.1111/cei.12206",
language = "English (US)",
volume = "175",
pages = "397--407",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Requirement for safety monitoring for approved multiple sclerosis therapies

T2 - An overview

AU - Rommer, P. S.

AU - Zettl, U. K.

AU - Kieseier, B.

AU - Hartung, H. P.

AU - Menge, T.

AU - Frohman, Elliot

AU - Greenberg, Benjamin

AU - Hemmer, B.

AU - Stuve, Olaf

PY - 2014/3

Y1 - 2014/3

N2 - Summary: During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk-benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appear to be more effective, but potential risks might be more severe. The potential complications of some novel therapies might not even have been identified to their full extent. This review is aimed at the clinical neurologist in that it offers insights into potential adverse events of each of the approved MS therapeutics: interferon beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod and teriflunomide, as well as recently approved therapeutics such as dimethyl fumarate and alemtuzumab. It also provides recommendations for monitoring the different drugs during therapy in order to avoid common side effects.

AB - Summary: During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk-benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appear to be more effective, but potential risks might be more severe. The potential complications of some novel therapies might not even have been identified to their full extent. This review is aimed at the clinical neurologist in that it offers insights into potential adverse events of each of the approved MS therapeutics: interferon beta, glatiramer acetate, mitoxantrone, natalizumab, fingolimod and teriflunomide, as well as recently approved therapeutics such as dimethyl fumarate and alemtuzumab. It also provides recommendations for monitoring the different drugs during therapy in order to avoid common side effects.

KW - Activation

KW - Acute respiratory distress syndrome

KW - Multiple sclerosis (MS)

UR - http://www.scopus.com/inward/record.url?scp=84893407969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893407969&partnerID=8YFLogxK

U2 - 10.1111/cei.12206

DO - 10.1111/cei.12206

M3 - Article

VL - 175

SP - 397

EP - 407

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -